Occlusion vs Standard Treatment for the Treatment of Herpes Zoster
Herpes Zoster
About this trial
This is an interventional treatment trial for Herpes Zoster
Eligibility Criteria
Inclusion Criteria:
- Patients with clinical diagnosis of HZ confirmed by a certified dermatologist
- Patients having maximum 72 hours from the start of the first vesicle
- Older than 18 years
Exclusion Criteria:
- Patients with dimethicone allergy
- Patients with hydrocolloid allergy
- Patients with acetaminophen allergy
- Patients with aluminium sulphate and calcium acetate allergy
- Patients with acyclovir allergy
- Pregnant women
- Breastfeeding women
- Unable to give informed consent
- Patients with signs of infection over the skin rash
- Patients with disseminated HZ
- Patients with hemorrhagic HZ
- Patients with complications such as pneumonia or encephalitis
- Patients unable to apply the treatment to the affected area
- Patients with HZ-associated keratitis
- Patients whose rash is located to hairy areas that may hinder occlusion with the hydrocolloid dressing.
Sites / Locations
- Hospital General Dr Manuel Gea GonzálezRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Group A: Aluminum sulphate and calcium acetate drying soaks
Group B: Topical sterile silicone gel for wounds
Group C: Hydrocolloid dressing
Group A will receive 10 minute soaks every 8 hours with a solution prepared with aluminum sulphate and calcium acetate powder (Domeboro® (Advaita Pharmaceuticals, México)) diluted in 500 ml of clean cold water.
Group B will receive topical silicone sterile gel for wounds (Stratamed gel®, (Stratapharma, Switzerland)) applied every 8 hours.
Group C will apply an extra thin hydrocolloid dressing to all the open areas (Duoderm Extra Thin® (Convatec, USA)) with dressing changes every 48 to 72 hours depending on the amount of wound exudate.